Literature DB >> 7208598

Dapsone in saliva and plasma of man.

J H Peters, J F Murray, G R Gordon, R H Gelber.   

Abstract

Concentrations of dapsone (DDS) and its metabolite, monoacetyl dapsone (MADDS) were measured in plasma and saliva samples collected concurrently from volunteers receiving a 50-mg oral dose of DDS. A liquid chromatographic technique was employed to separate the compounds from each other and from endogenous materials. Fluorescence detection provided limited sensitivities to 0.1 ng/ml of sample. Saliva levels of DDS were consistently 15-20% of the plasma levels of DDS during the study period, which ranged from 4 to 48 h. Decay rates for DDS from saliva and plasma were nearly identical. In 4-hour samples of plasma subjected to equilibrium dialysis, we found amounts of DDS in the dialysates nearly identical to levels found in saliva collected at that time. Saliva levels of MADDS ranged from 0.8 to 2.6% of their plasma levels at all times. Decay rates of MADDS from the two fluids were nearly identical and saliva levels of MADDS in 4-hour samples were nearly identical to levels found in paired plasma dialysates. Nevertheless, levels of MADDS were so low that a reliable definition of the subjects' acetylator phenotype from levels of MADDS in saliva only was impossible.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7208598     DOI: 10.1159/000137486

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  12 in total

1.  Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.

Authors:  F A Pieters; F Woonink; J Zuidema
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  The pharmacokinetics of dapsone after oral administration to healthy volunteers.

Authors:  F A Pieters; J Zuidema
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 3.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

4.  Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.

Authors:  M D Edstein; K H Rieckmann; J R Veenendaal
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

5.  Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.

Authors:  W T Hughes
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of dapsone.

Authors:  J Zuidema; E S Hilbers-Modderman; F W Merkus
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

Review 7.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

8.  N-acetylation phenotyping with dapsone in a mainland Chinese population.

Authors:  Y Horai; H H Zhou; L M Zhang; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

9.  N-acetylation phenotyping using dapsone in a Jordanian population.

Authors:  Y M Irshaid; H F al-Hadidi; M A Abuirjeie; N M Rawashdeh
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

10.  Excretion of chloroquine, dapsone and pyrimethamine in human milk.

Authors:  M D Edstein; J R Veenendaal; K Newman; R Hyslop
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.